Lipid Nanoparticles for Gene Therapy via Polysaccharide Shielding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges with low transfection efficacy and safety concerns due to immunogenicity and oncogenicity issues with viral vectors, and limitations in the size of genetic material that can be transferred, while non-viral systems often suffer from low efficiency and instability during systemic administration.
Innovation Solution
A lipid nanoparticle system incorporating a polysaccharide and a positively charged peptide, with a structure comprising a lipophilic core, a hydrophilic phase with cationic and non-ionic surfactants, and a biologically active molecule, which protects genetic material from enzymatic degradation and enhances cell uptake and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene therapy, then transfection efficacy is improved, but immunogenicity and oncogenicity problems occur
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier to deliver genetic material into cells, replacing viral vectors. The lipid nanoparticle system includes ionizable lipids, helper lipids, and surfactants that facilitate cellular uptake without triggering immune responses or oncogenicity, thus resolving the contradiction between high transfection efficacy and safety concerns
Solution Approach 2:
The patent employs ionizable lipids that change their charge state based on pH - they are positively charged in acidic environments (facilitating DNA complexation and cellular uptake) and neutral in physiological pH (reducing immunogenicity). This parameter change allows the system to achieve high transfection efficacy while minimizing harmful effects
2Object-affected harmful factors
If non-viral transfection systems are used, then safety is improved, but transfection efficacy is reduced
Solution Approach 1:
The patent creates a composite lipid nanoparticle system combining multiple components: ionizable lipids (for DNA complexation and membrane disruption), helper lipids (for structural stability), and surfactants (for solubility and cellular uptake enhancement). This composite structure achieves transfection efficacy comparable to or exceeding viral vectors while maintaining the safety advantages of non-viral systems
Solution Approach 2:
The patent structures the genetic material (DNA or RNA) nested within the lipid nanoparticle core, where ionizable lipids form a condensed complex with the nucleic acid. This nested structure protects the genetic material during circulation and delivery, then facilitates its release into the cell cytoplasm, achieving both safety and high transfection efficacy
3Adaptability or versatility
If genetic material is administered systemically, then treatment coverage is improved, but enzymatic degradation increases
Solution Approach 1:
The patent uses a flexible lipid nanoparticle shell that encapsulates the genetic material, protecting it from enzymatic degradation during systemic circulation. The lipid bilayer structure acts as a barrier against nucleases and other degrading enzymes in the bloodstream, maintaining genetic material integrity from administration site to target tissue
Solution Approach 2:
The lipid nanoparticle serves as an intermediary protective layer between the genetic material and the harsh systemic environment. This carrier system shields the vulnerable nucleic acid from enzymatic attack while still allowing targeted delivery to specific tissues through passive or active mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves high transfection efficacy and cell viability, effectively delivering genetic material to cells, including spleen and liver cells, and maintains gene expression over time, offering a safer and more efficient alternative to viral vectors.
Implementation Method 1
said hydrophilic phase comprising at least one cationic surfactant and at least one non-ionic surfactant; at least one biologically active molecule; and at least one polysaccharide, wherein said polysaccharide comprises the bonding of at least three monosaccharides
Data Source
Figure 1A~2
Figure 3~5
Figure 6~7
AI summary
The present invention relates to a lipid nanoparticle system comprising a lipid component, a cationic surfactant, a non-ionic surfactant, a polysaccharide and, optionally, a positively charged peptide, useful for the release of pharmacologically active molecules, and especially for transfecting genetic material into cells and/or tissues. It also relates to methods for obtaining nanoparticles, to pharmaceutical compositions comprising it, as well as to the use thereof in gene therapy.